Pharma BD Deal Intelligence

Roche Holding AG / Syntex Corporation

1994 · Acquisition/Merger · $5.3B · Complete

Announcement Sentiment

Neutral / mixed

Outcome Score

Mixed — partial payoff, real shortfalls.

Roche Holding acquired Syntex Corporation for $5.3 billion ($24/share in cash), making Roche the fourth-largest pharmaceutical company in the world. The deal strengthened Roche's US presence and added Syntex's anti-inflammatory and hormonal drug portfolio.

Key facts

Announced May 01, 1994
Closed Nov 01, 1994
Deal value $5.3B
Deal type Acquisition/Merger
Therapeutic area Dermatology, Immunology, Neurology, Women's Health
Indications Pain/Inflammation, Dermatologic Conditions
Key assets Naprosyn (naproxen), Synalar (fluocinolone), Syntex R&D pipeline, Palo Alto research campus
Mechanism COX inhibitor, Corticosteroid

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals